TELA BIO INC. - COMMO

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

16 авг 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Reports Second Quarter 2023 Financial Results

09 авг 2023 13:03:00 Источник Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 авг 2023 13:02:00 Источник Nasdaq GlobeNewswire

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

26 июл 2023 04:00:00 Источник Nasdaq GlobeNewswire

New Survey Finds Strong Consumer Preference for More Natural Hernia Repair Options

15 июн 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio to Participate in the Jefferies Global Healthcare Conference

25 май 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab

19 май 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Reports First Quarter 2023 Financial Results

11 май 2023 13:02:00 Источник Nasdaq GlobeNewswire

TELA Bio Supports Diversity and Inclusion at International Hernia Collaboration Conference

09 май 2023 04:00:01 Источник Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 май 2023 13:30:00 Источник Nasdaq GlobeNewswire

TELA Bio to Participate in the JMP Securities Life Sciences Conference

02 май 2023 04:00:01 Источник Nasdaq GlobeNewswire

TELA Bio to Announce First Quarter 2023 Financial Results

27 апр 2023 04:00:01 Источник Nasdaq GlobeNewswire

TELA Bio Announces Pricing of Public Offering of Common Stock

18 апр 2023 20:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Announces Proposed Public Offering of Common Stock

18 апр 2023 13:01:00 Источник Nasdaq GlobeNewswire

TELA Bio’s OviTex® Reinforced Tissue Matrix to be Featured in Three Case Reports at SAGES 2023

29 мар 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Announces 510(k) Clearance for OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

23 мар 2023 04:00:01 Источник Nasdaq GlobeNewswire

TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results

21 мар 2023 13:02:00 Источник Nasdaq GlobeNewswire

TELA Bio Highlights Published Clinical Research from 2022 Showcasing Safety and Performance of Reinforced Biologic for Hernia Indications

16 мар 2023 04:00:00 Источник Nasdaq GlobeNewswire

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 фев 2023 13:02:00 Источник Nasdaq GlobeNewswire

TELA Bio Announces U.S. Commercial Launch of Two New OviTex® LPR Device Configurations to Repair Large Abdominal Hernias Using Robotic and Laparoscopic Techniques

21 фев 2023 04:00:00 Источник Nasdaq GlobeNewswire